Evidence map›Paper›PMID 39165610›Full record

ArticleResearch and practice in thrombosis and haemostasis2024

Primary postpartum hemorrhage in women with von Willebrand disease and carriers of hemophilia: a retrospective analysis.

Marieke Punt, Fe van Leusden, Kitty Bloemenkamp, Michiel Coppens, Mariette Driessens, Floor Heubel-Moenen, Titia Lely, Anja Mäkelburg, Laurens Nieuwenhuizen, Saskia Haitjema and 7 more

Abstract read
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. von Willebrand disease: an illustrated review.Research and practice in thrombosis and haemostasis · 2026
    Review
  2. Observational
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marieke PuntUniversity Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, the Netherlands.
Fe van LeusdenUniversity Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, the Netherlands.
Kitty BloemenkampDepartment of Gynecology and Obstetrics, Utrecht, the Netherlands.
Michiel CoppensDepartment of Vascular Medicine, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, the Netherlands.
Mariette DriessensNetherlands Hemophilia Patient Society, Nijkerk, the Netherlands.
Floor Heubel-MoenenDepartment of Haematology-Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands.
Titia LelyDepartment of Gynecology and Obstetrics, Utrecht, the Netherlands.
Anja MäkelburgDepartment of Hematology, University Medical Center Groningen, Groningen, the Netherlands.
Laurens NieuwenhuizenHemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, the Netherlands.
Saskia HaitjemaUniversity Medical Center Utrecht, University Utrecht, Laboratory of Clinical Chemistry and Hematology, Utrecht, the Netherlands.
Wouter van SolingeUniversity Medical Center Utrecht, University Utrecht, Laboratory of Clinical Chemistry and Hematology, Utrecht, the Netherlands.
Joline SaesHemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, the Netherlands.
Saskia ScholsHemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, the Netherlands.
Roger SchutgensUniversity Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, the Netherlands.
Jeroen EikenboomDepartment of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
Marieke KruipDepartment of Hematology Erasmus MC, Erasmus University Medical Center, Rotterdam, the Netherlands.
Karin van GalenUniversity Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Between 2002 and 2011, the incidence of severe primary postpartum hemorrhage (PPH) in Dutch women with von Willebrand disease (VWD) and hemophilia carriers (HCs) was 8% vs 4.5% in the general population. Objectives: To determine the contemporary incidence of severe primary PPH in women with VWD and HCs. Methods: All women with VWD or HCs who delivered between 2012 and 2017 were selected from all 6 Dutch hemophilia treatment centers. Data on patient and disease characteristics, peripartum hematologic and obstetric management, and outcomes were retrospectively collected. Incidence of severe primary (≥1000 mL of blood loss ≤24 hours after childbirth) and primary (≥500 mL within ≤24 hours after childbirth) PPH was compared with the (1) previous cohort and (2) general Dutch population and between (3) women with VWD and HCs with third-trimester coagulation activity levels <50 international units (IU)/dL vs ≥50 IU/dL and (4) women treated with vs without peripartum hemostatic prophylaxis. Results: Three-hundred forty-eight deliveries (151 VWD, 167 hemophilia A, and 30 hemophilia B carriers) were included. The severe primary PPH incidence was 10% (36/348) and remained stable over time, whereas this incidence has increased in the general population (to 8%), leading to a similar risk ( Conclusion: Severe primary PPH in women with VWD and HCs remained stable and is comparable with the increasing prevalence in the general population. More research is needed to find the optimal pregnancy management strategy for safe delivery in VWD and HC.

Indexed as

hemophilia Ahemophilia Bpostpartum hemorrhagepregnancyvon Willebrand diseases

Identifiers

PMID39165610
PMCPMC11334897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.